Pegcetacoplan
Pre-clinicalActive 0 watching 0 views this week💤 Quiet
18
Development Stage
1
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Geographic Atrophy
Conditions
Geographic Atrophy
Trial Timeline
Sep 28, 2023 → Jun 1, 2027
NCT ID
NCT06161584About Pegcetacoplan
Pegcetacoplan is a pre-clinical stage product being developed by Apellis Pharmaceuticals for Geographic Atrophy. The current trial status is active. This product is registered under clinical trial identifier NCT06161584. Target conditions include Geographic Atrophy.
Hype Score Breakdown
Clinical
5
Activity
2
Company
5
Novelty
2
Community
1
Clinical Trials (14)
| NCT ID | Phase | Status |
|---|---|---|
| NCT04729062 | Pre-clinical | Completed |
| NCT07020832 | Phase 3 | Recruiting |
| NCT06161584 | Pre-clinical | Active |
| NCT05809531 | Phase 3 | Active |
| NCT05067127 | Phase 3 | Completed |
| NCT04572854 | Phase 2 | Active |
| NCT04901936 | Phase 2 | Recruiting |
| NCT03531255 | Phase 3 | Active |
| NCT03593200 | Phase 2 | Completed |
| NCT03465709 | Phase 1/2 | Terminated |
| NCT02588833 | Phase 1 | Completed |
| NCT02503332 | Phase 2 | Completed |
| NCT02264639 | Phase 1 | Completed |
| NCT02461771 | Phase 1 | Completed |
Competing Products
20 competing products in Geographic Atrophy
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| avacincaptad pegol | Astellas Pharma | Phase 3 | 77 |
| Avacincaptad Pegol | Astellas Pharma | Phase 2/3 | 65 |
| avacincaptad pegol | Astellas Pharma | Approved | 85 |
| Avacincaptad pegol (ACP) | Astellas Pharma | Pre-clinical | 23 |
| Avacincaptad Pegol + Sham | Astellas Pharma | Phase 3 | 77 |
| ABBV-6628 + SYFOVRE | AbbVie | Phase 1/2 | 41 |
| FWY003 + Placebo | Novartis | Phase 2 | 52 |
| CLG561 + LFG316 + Sham injection | Novartis | Phase 2 | 52 |
| LFG316 + Sham + LFG316 Lower dose | Novartis | Phase 2 | 52 |
| Lampalizumab | Roche | Phase 3 | 77 |
| Lampalizumab | Roche | Phase 3 | 77 |
| Lampalizumab | Roche | Phase 3 | 77 |
| RO7669330 + Syfovre™ + Izervay™ | Roche | Phase 1 | 33 |
| RO7303359 | Roche | Phase 1 | 33 |
| SAR446597 + Sham Comparator | Sanofi | Phase 1/2 | 40 |
| Pozelimab | Regeneron Pharmaceuticals | Phase 1 | 32 |
| IONIS-FB-Lrx + Placebo (sterline saline 0.9%) | Ionis Pharmaceuticals | Phase 2 | 49 |
| Tinlarebant + Placebo | Belite Bio | Phase 3 | 74 |
| APL-2 + APL-2 | Apellis Pharmaceuticals | Phase 3 | 72 |
| APL-2, Pegcetacoplan | Apellis Pharmaceuticals | Phase 3 | 72 |